REGISTERED NUMBER: 07022086 (England and Wales)

Unaudited Financial Statements

for the Year Ended 31st March 2019

for

LONDON HAEMATOLOGY LIMITED

Contents of the Financial Statements for the year ended 31st March 2019

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	4
Chartered Accountants' Report	7

LONDON HAEMATOLOGY LIMITED

Company Information for the year ended 31st March 2019

DIRECTORS: Dr R Jan-Mohamed

Dr R Kaczmarski Dr M N Potter Prof J G Gribben

REGISTERED OFFICE: Suffolk House

George Street Croydon Surrey CRO 0YN

REGISTERED NUMBER: 07022086 (England and Wales)

ACCOUNTANTS: Simpson Wreford & Partners

Chartered Accountants

Suffolk House George Street Croydon Surrey CRO 0YN

Balance Sheet 31st March 2019

		31.3.19		31.3.18	
	Notes	£	£	£	£
FIXED ASSETS					
Intangible assets	4		160,000		480,000
Property, plant and equipment	5		1,235_		1,853
			161,235		481,853
CURRENT ASSETS					
Debtors	6	614,864		616,515	
Cash at bank		204,644		<u>157,083</u>	
		819,508		773,598	
CREDITORS					
Amounts falling due within one year	7	204,109		275,230	
NET CURRENT ASSETS			615,399		498,368
TOTAL ASSETS LESS CURRENT LIABILITIES			776,634		980,221
CAPITAL AND RESERVES					
Called up share capital			100		100
Retained earnings			776,534		980,121
			776,634		980,221

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2019.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2019 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
 - preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of
- Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Balance Sheet - continued 31st March 2019

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors on 1st May 2019 and were signed on its behalf by:

Prof J G Gribben - Director

Dr R Jan-Mohamed - Director

Dr R Kaczmarski - Director

Dr M N Potter - Director

Notes to the Financial Statements for the year ended 31st March 2019

1. STATUTORY INFORMATION

London Haematology Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Revenue is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill

Goodwill, being the amount paid in connection with the acquisition of a business in 0, is being amortised evenly over its estimated useful life of nil years.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. Plant and machinery etc - 25% on cost

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

Page 4 continued...

Notes to the Financial Statements - continued for the year ended 31st March 2019

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 7 (2018 - 7).

4	INTANGIE	REFIXED	ASSETS

4.	INTANGIBLE FIXED ASSETS		
			Goodwill
			£
	COST		
	At 1st April 2018		
	and 31st March 2019		3,200,000
	AMORTISATION		
	At 1st April 2018		2,720,000
	Charge for year		320,000
	At 31st March 2019		3,040,000
	NET BOOK VALUE		_
	At 31st March 2019	_	160,000
	At 31st March 2018		480,000
5.	PROPERTY, PLANT AND EQUIPMENT		
	,		Plant and
			machinery
			etc
			£
	COST		
	At 1st April 2018		
	and 31st March 2019		234,876
	DEPRECIATION		
	At 1st April 2018		233,023
	Charge for year		618
	At 31st March 2019		233,641
	NET BOOK VALUE		
	At 31st March 2019		1,235
	At 31st March 2018		1,853
6.	DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
•		31.3.19	31.3.18
		£	£
	Trade debtors	589,477	592,315
	Other debtors	-	2,585
	Prepayments	25,387	21,615
		614,864	616,515

Page 5 continued...

Notes to the Financial Statements - continued for the year ended 31st March 2019

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	31.3.19	31.3.18
	£	£
Tax	136,445	219,732
Social security and other taxes	21,211	3,859
Net wages	-	(3,500)
Other creditors	783	583
Directors' loan accounts	43,170	50,776
Accrued expenses	2,500	3,780
	204,109	275,230

Chartered Accountants' Report to the Board of Directors on the Unaudited Financial Statements of London Haematology Limited

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of London Haematology Limited for the year ended 31st March 2019 which comprise the Income Statement, Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed within the ICAEW's regulations and guidance at http://www.icaew.com/en/membership/regulations-standards-and-guidance.

This report is made solely to the Board of Directors of London Haematology Limited, as a body, in accordance with our terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of London Haematology Limited and state those matters that we have agreed to state to the Board of Directors of London Haematology Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than London Haematology Limited and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that London Haematology Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of London Haematology Limited. You consider that London Haematology Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of London Haematology Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.

Simpson Wreford & Partners Chartered Accountants Suffolk House George Street Croydon Surrey CRO 0YN

1st May 2019

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.